Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Dan LiuFurong KouJifang GongZhiqiang WangXiaotian ZhangJian LiYan LiJie LiJun ZhouMing LuXicheng WangZhihao LuYanshuo CaoJianjun ZouXiaoyu ZhuRuihua XuLin ShenPublished in: Cancer medicine (2023)
This study was registered with ClinicalTrials.gov, NCT02378389.